


AUSTRALIA BIOTECH INVEST & PARTNERING 2018

Connecting capital with innovation

Tuesday 30 October
Sofitel Melbourne on Collins
ausbiotechinvestment.com.au

#AusBioInv



TESSARA THERAPEUTICS

Company profile

Tessara Therapeutics Pty Ltd

"The new dimension in regenerative medicine"

About us: Tessara Therapeutics Pty Ltd is an Australian regenerative medicine company developing *RealBrain™*, a synthetic human brain tissue for several commercial applications.

Research applications: Tessara uses *RealBrain* technology to address major unmet needs in CNS drug development: translation from *in vitro* to *in vivo*, and from animal to human physiology. As a drug screening tool, *RealBrain* CNS tissue provides unprecedented insights into toxicology and efficacy in a human *in vitro* model.

Therapeutic applications: TSR-101 is a novel cell-replacement therapy for neurological diseases. TSR-101 has compositional superiority over competing technologies to overcome persistent challenges in regenerative medicine.

Technology: To produce *RealBrain™* synthetic human CNS tissue, Tessara uses a proprietary polymer matrix with a defined composition of clinically approved biomaterials to mimic human brain physiology and direct the development of functional neural networks from human neural stem cells in a highly controllable and reproducible manner (*Published in a peer-reviewed journal, 2018*). Tessara's products are well positioned for market exclusivity, leveraging patents, manufacturing know-how and other robust proprietary advantages.



AUSTRALIA BIOTECH INVEST & PARTNERING 2018

Connecting capital with innovation

Tuesday 30 October
Sofitel Melbourne on Collins
ausbiotechinvestment.com.au

#AusBioInv



Speaker profile



Dr Christos Papadimitriou is the CEO and Managing Director of Tessara Therapeutics. He is the inventor of *RealBrain™*, a human synthetic CNS tissue that Tessara is developing for commercial drug screening and CNS therapeutics.

A serial entrepreneur, Christos is an award-winning qualified neuroscientist with solid experience in commercialisation.

He has been working in the field of regenerative medicine at world-class institutes, including Johns Hopkins Medical School, ETH Zurich, EMBL Heidelberg and the German Center for Neurodegenerative Diseases, to develop regenerative medicine applications with commercial focus. Christos is highly skilled at identifying commercial opportunities and creating spin-out entities to commercialise new IP in the pharmaceuticals and health-care space.

Dr Papadimitriou is currently consulting to biotechnology companies globally as a Business Development Manager of Bio-Link Australia.